Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company's lead product candidate is nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, which is in Phase 2 clinical trial. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Skye Bioscience, Inc.

Skye Bioscience ( ($SKYE) ) has issued an announcement. On August 14, 2026, Skye Bioscience agreed to acquire U.K.-based Redx Pharma, combining to ...

Skye Bioscience to Merge with Redx, Form Fibrx Therapeutics

Vanguard S&P 500 ETF ($VOO) and Vanguard Total Stock Market ETF ($VTI) rank among the most popular exchange-traded funds in the U.S. Together, they...

VOO vs VTI: Are You Owning the Wrong Vanguard ETF?

Skye Bioscience (SKYE) is facing an investor securities lawsuit in the U.S. District Court for the Southern District of California, where sharehold...

Skye Bioscience Lawsuit: MFDI Seeks Dismissal of Securities Claims Against It 

Skye Bioscience (SKYE) and its chief executive officer, Punit Dhillon, have asked a federal court in California to dismiss the claims against them ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SKYE	$0.50	0.00%	37.50K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SKYE	$0.50	0%	37.50K
3
4
5
6

SKYE

Get Skye Bioscience, Inc. Data in Excel

Get Skye Bioscience, Inc. Data in Excel